Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
GABAergic interneurons contribute to the fatal seizure phenotype of CLN2 disease mice
Keigo Takahashi, … , Mark S. Sands, Jonathan D. Cooper
Keigo Takahashi, … , Mark S. Sands, Jonathan D. Cooper
Published August 21, 2025
Citation Information: JCI Insight. 2025;10(19):e184487. https://doi.org/10.1172/jci.insight.184487.
View: Text | PDF
Research Article Genetics Neuroscience

GABAergic interneurons contribute to the fatal seizure phenotype of CLN2 disease mice

  • Text
  • PDF
Abstract

The cellular etiology of seizures in CLN2 disease, a childhood-onset neurodegenerative lysosomal storage disorder caused by a deficiency of tripeptidyl peptidase 1 (TPP1), remains elusive. Given that Cln2R207X/R207X mice display fatal spontaneous seizures and an early loss of several cortical GABAergic interneuron populations, we hypothesized that these 2 events might be causally related. To study the cell-autonomous effects of interneuron-specific TPP1 deficiency, we first generated transgenic mice expressing loxP-flanked lysosomal membrane–tethered TPP1 (TPP1LAMP1 mice) on the Cln2R207X/R207X genetic background, and then crossed TPP1LAMP1 mice with Vgat-Cre mice. These Vgat-Cre; TPP1LAMP1 mice accumulated storage material in cortical and striatal interneurons. Vgat-Cre; TPP1LAMP1 mice also died more readily after pentylenetetrazole-induced seizures, indicating that interneuron-specific TPP1 deficiency renders these mice more susceptible to seizure-induced mortality. We also selectively activated interneurons using designer receptors exclusively activated by designer drugs (DREADDs) in Vgat-Cre; Cln2R207X/R207X mice. Electroencephalogram monitoring revealed that DREADD-mediated activation of interneurons markedly accelerated the onset of spontaneous seizures and seizure-associated death in Vgat-Cre; Cln2R207X/R207X mice, suggesting that modulating interneuron activity can exacerbate epileptiform abnormalities. Taken together, these results provide mechanistic insights into the underlying etiology of seizures and premature death that characterize CLN2 disease.

Authors

Keigo Takahashi, Nicholas R. Rensing, Elizabeth M. Eultgen, Letitia L. Williams, Sophie H. Wang, Hemanth R. Nelvagal, Steven Q. Le, Marie S. Roberts, Balraj Doray, Edward B. Han, Patricia I. Dickson, Michael Wong, Mark S. Sands, Jonathan D. Cooper

×

Figure 4

Interneuron-specific TPP1 deficiency increases susceptibility to sudden death secondary to pentylenetetrazole-induced seizures.

Options: View larger image (or click on image) Download as PowerPoint
Interneuron-specific TPP1 deficiency increases susceptibility to sudden ...
(A) CatWalk XT gait analysis reveals preserved gait performance of Vgat-Cre; TPP1LAMP1 mice (purple) compared with TPP1LAMP1 and Cln2R207X/R207X mice at 15 weeks of age (n = 10 per group). (B) Seizures were induced by intraperitoneal injection of pentylenetetrazole (PTZ; 75 mg/kg) in TPP1LAMP1 (n = 12, green bars) and Vgat-Cre; TPP1LAMP1 (n = 9, purple bars) mice at 25 weeks of age. There was no significant difference in the latency to tonic-clonic seizures between 2 groups. Vgat-Cre; TPP1LAMP1 mice exhibit a significantly lower number of tonic-clonic seizures per mouse and a significantly shorter time to death compared with TPP1LAMP1 mice. The average duration of nonfatal tonic-clonic seizures in TPP1LAMP1 mice was significantly shorter than the average duration of fatal tonic-clonic seizures in TPP1LAMP1 mice and Vgat-Cre; TPP1LAMP1 mice. Dots represents values from individual animals. Values are shown as mean ± SEM. One-way ANOVA with Bonferroni’s correction (A) and unpaired, 2-tailed t test (B). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts